相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regulation of podocalyxin expression in the kidney of streptozotocin-induced diabetic rats with Chinese herbs (Yishen capsule)
Jingai Fang et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2013)
Modulation of thioacetamide-induced liver fibrosis/cirrhosis by sildenafil treatment
Eman Said et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2013)
Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of Doxorubicin
John Wong et al.
CANCER BIOLOGY & THERAPY (2013)
Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes
Patricia O. Prada et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin
Yoshikiyo Ito et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin
M. Hara et al.
DIABETOLOGIA (2012)
Nilotinib protects the murine liver from ischemia/reperfusion injury
Lee M. Ocuin et al.
JOURNAL OF HEPATOLOGY (2012)
Toll-Like Receptor 4 Promotes Tubular Inflammation in Diabetic Nephropathy
Miao Lin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib
Yuqing Liu et al.
JOURNAL OF HEPATOLOGY (2011)
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
Masayuki Iyoda et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies
J. H. W. Distler et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W. Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
Paul W. Manley et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
The Neural Stem/Progenitor Cell Marker Nestin Is Expressed in Proliferative Endothelial Cells, but Not in Mature Vasculature
Sayuri Suzuki et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2010)
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
Nicole M Agostino et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Proliferation of Immature Tumor Vessels Is a Novel Marker of Clinical Progression in Prostate Cancer
Karsten Gravdal et al.
CANCER RESEARCH (2009)
Diabetic nephropathy
Themis Zelmanovitz et al.
DIABETOLOGY & METABOLIC SYNDROME (2009)
Imatinib Mesylate and AMN107 Inhibit PDGF-Signaling in Orbital Fibroblasts: A Potential Treatment for Graves' Ophthalmopathy
Leendert van Steensel et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib
Elizabeth Day et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
Alfiya Akhmetshina et al.
FASEB JOURNAL (2008)
Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-Abl
Amina El Jamali et al.
FREE RADICAL BIOLOGY AND MEDICINE (2008)
TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity
Binzhi Zhang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Cedric Louvet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Glomerular hypertrophy precedes albuminuria and segmental loss of podoplanin in podocytes in Munich-Wistar-Fromter rats
D. H. T. IJpelaar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Pathogenesis of the Podocytopathy and Proteinuria in Diabetic Glomerulopathy
Fuad N. Ziyadeh et al.
CURRENT DIABETES REVIEWS (2008)
Soluble guanylyl cyclase activation promotes angiogenesis
Anastasia Pyriochou et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Neurogenic effect of vascular endothelial growth factor during germ layer formation of human embryonic stem cells
Byung-Kak Kim et al.
FEBS LETTERS (2006)
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
M Golemovic et al.
CLINICAL CANCER RESEARCH (2005)
Regulation of angiogenesis by hypoxia: role of the HIF system
CW Pugh et al.
NATURE MEDICINE (2003)
Nephrin expression is reduced in human diabetic nephropathy - Evidence for a distinct role for glycated albumin and angiotensin II
S Doublier et al.
DIABETES (2003)
Cell biology of the glomerular podocyte
H Pavenstadt et al.
PHYSIOLOGICAL REVIEWS (2003)
Regulation of α-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts
SG Roy et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2001)
Nephrin in experimental glomerular disease
P Luimula et al.
KIDNEY INTERNATIONAL (2000)
分享论文
